Skip to main content
Home / News and Insights / News / BDB Pitmans advises N+1 Singer on a placing and subscription to raise $50 million for Summit Therapeutics plc
COVID-19 – Important information for clients Read More
20 January 2020

BDB Pitmans advises N+1 Singer on a placing and subscription to raise $50 million for Summit Therapeutics plc

Leading law firm, BDB Pitmans, was instructed by investment bank N+1 Singer, in a placing and subscription of new ordinary shares and warrants for Summit Therapeutics plc (‘Summit’), to raise $50 million from Summit’s existing shareholders.

BDB Pitmans worked alongside counsel in the United States as Summit’s US shareholders were also being approached to invest in the fundraising. Additionally, the transaction included proposals to restructure Summit Therapeutics’ board of directors, with the firm’s new majority shareholder proposing appointing a new board and delisting Summit from the Alternative Investment Market (AIM), whilst maintaining the firm’s listing on Nasdaq.

The BDB Pitmans team was led by corporate partner Nick McCarthy who worked alongside corporate legal director Andrew McGlashan. CMS acted for Summit Therapeutics.

Nick McCarthy comments:

‘This deal was particularly interesting and complex, given Summit Therapeutics’ cross-border shareholder base. The successful outcome of the deal reflects the capability of the BDB Pitmans team to advise clients on unique and challenging legal matters.’

Related Articles

Our Offices

London
50 Broadway, London
SW1H 0BL

Cambridge
50/60 Station Road
Cambridge
CB1 2JH

Reading
The Anchorage, 34 Bridge Street
Reading RG1 2LU

Southampton
Grosvenor House, Grosvenor Square
Southampton SO15 2BE

 

Reading
The Anchorage, 34 Bridge Street
Reading RG1 2LU

Southampton
Grosvenor House, Grosvenor Square
Southampton SO15 2BE

Follow us

  • Pay my invoice
  • Lexcel
  • CYBER ESSENTIALS PLUS

© BDB Pitmans 2020. 50 Broadway, London, SW1H 0BL - T +44 (0)345 222 9222